MedPath

ImmuPharma (LON:IMM) Trading Down 7.3% - Here's Why

ImmuPharma plc experienced a 7.3% decrease in its stock price on Friday, with shares trading as low as GBX 1.07. The company, known for developing peptide-based therapeutics, has a market capitalization of £4.79 million and is currently conducting a Phase III clinical trial for its lead product candidate, Lupuzor, aimed at treating lupus.

ImmuPharma plc (LON:IMM) traded down 7.3% on Friday. The stock traded as low as GBX 1.07 ($0.01) and last traded at GBX 1.15 ($0.01). 269,778 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 1,793,761 shares. The stock had previously closed at GBX 1.24 ($0.02).

ImmuPharma Stock Performance

The company has a market capitalization of £4.79 million, a price-to-earnings ratio of -115.00 and a beta of 1.53. The business’s 50 day moving average is GBX 1.46 and its 200 day moving average is GBX 1.71.

ImmuPharma Company Profile

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Mersana Therapeutics Stock Drops Following Phase 1 Trial Data Release

Mersana Therapeutics Inc. saw its stock price drop by 36.6% after releasing initial data from the Phase 1 trial of emiltatug ledadotin, despite showing promising results in treating B7-H4 high tumors and triple-negative breast cancer.

IGM Biosciences Halts Autoimmune Programs, Imvotamab and IGM-2644, Following Disappointing Phase 1b Results

IGM Biosciences has stopped the development of imvotamab and IGM-2644 after Phase 1b trials showed insufficient B cell depletion in rheumatoid arthritis and lupus patients.
The company is reducing its workforce by 73% to preserve cash and is exploring strategic alternatives, including a potential sale or merger.

ImmuPharma (LON:IMM) Stock Price Down 5.6%

ImmuPharma plc's stock price decreased by 5.6% on Friday, trading at GBX 1.15 after reaching a low of GBX 1.03. The trading volume was approximately 845,057 shares, marking a 7% decline from the average daily volume.

Keros Therapeutics Halts Cibotercept Trial Dosing Due to Safety Concerns, Stock Plummets

Keros Therapeutics stopped dosing in two arms of a Phase 2 trial of cibotercept for pulmonary arterial hypertension (PAH) due to safety concerns, specifically pericardial effusion.
The company's stock price plunged 73% following the announcement, wiping out over $2 billion in market value, as investors lost confidence in the drug's potential.

Pharma Share Moves of 2024: Lilly and Vertex Rise, Pfizer and Merck Decline

Eli Lilly's shares surged by 37% YTD, driven by the success of Zepbound for weight loss and advancements in its Alzheimer's treatment, Kisunla.
Pfizer's shares declined by over 10% due to normalization of COVID-19 business and patent cliffs, despite efforts to transition Paxlovid to a commercial market.

Eyenovia's Stock Plummets After Phase III Myopia Study Fails

Eyenovia discontinued its Phase III CHAPERONE study for MicroPine, a low-dose atropine treatment for pediatric progressive myopia, after it failed to meet the primary endpoint.
An independent Data Review Committee found no significant difference in myopia progression between the treatment arms and placebo in the study of 252 patients.

Syros' Tamibarotene Fails in Phase III Trial for Higher-Risk Myelodysplastic Syndrome

Syros Pharmaceuticals' stock plummeted after its Phase III SELECT-MDS-1 trial of tamibarotene plus azacitidine failed to meet the primary endpoint in higher-risk myelodysplastic syndrome (HR-MDS) patients.
The trial, involving 190 patients, showed similar complete response rates in both the treatment (23.8%) and placebo (18.8%) groups, leading to the discontinuation of the study.

Syros' Tamibarotene Fails Phase III Trial in Higher-Risk Myelodysplastic Syndrome

Syros Pharmaceuticals' stock plummeted after its Phase III SELECT-MDS-1 trial of tamibarotene plus azacitidine failed to meet the primary endpoint.
The trial focused on newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression.

Syros' Tamibarotene Fails in Phase III Trial for Higher-Risk Myelodysplastic Syndrome

Syros Pharmaceuticals' stock plummeted after its Phase III SELECT-MDS-1 trial of tamibarotene plus azacitidine failed to meet the primary endpoint in higher-risk myelodysplastic syndrome (HR-MDS) patients.
The trial, involving 190 patients with RARA gene overexpression, showed similar complete response rates in both the treatment (23.8%) and placebo (18.8%) groups.

Sarepta's Gene Therapy Fails Primary Endpoint in Duchenne Muscular Dystrophy Trial

Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy (DMD) did not meet its primary endpoint in a Phase III trial, raising concerns about its efficacy in older children.
The trial, involving 125 young patients, aimed to demonstrate a slowing of disease progression over one year, but the results did not show a statistically significant benefit.

Reference News

[1]
ImmuPharma (LON:IMM) Trading Down 7.3% - Here's Why
etfdailynews.com · Dec 27, 2024

ImmuPharma plc's stock fell 7.3% to GBX 1.15, with a significant drop in trading volume. The company, specializing in pe...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy